Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HistologTM Scanner

Financiado

Cerrado

Intra operative microscope for tumor margin assessment

Breast Cancer is the most common cancer type and main cause of cancer related death in women worldwide. One in eight women in the EU and US will develop breast cancer in their lifetime. Breast-Conserving Surgery (BCS) also called... ver más

31/08/2021

SAMAN TREE MEDICAL...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

SAMAN TREE MEDICAL SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-08-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

SAMAN TREE MEDICAL SA

2.32M€ | Lider

PLASTICOS DUREX

384.72K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TRIOP TRIOP: an intraoperative probe to assess tumor margins and r... 75K€ Cerrado

Olfactomics Bringing Surgery to the 21st Century Feasibility Verificati... 71K€ Cerrado

ONCOscanner ONCOscanner oncological probe for intra operative identifi... 71K€ Cerrado

CLI The CLIO consortium Optimization of Cerenkov Luminescence I... 2M€ Cerrado

CerISMA Cerenkov Imaging for Surgical Margin Assessment 2M€ Cerrado

HELiCoiD HypErspectraL Imaging Cancer Detection 1M€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2018-08-07
Fecha Fin: 2021-08-31

Líder del proyecto

SAMAN TREE MEDICAL SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Breast Cancer is the most common cancer type and main cause of cancer related death in women worldwide. One in eight women in the EU and US will develop breast cancer in their lifetime. Breast-Conserving Surgery (BCS) also called lumpectomy is a standard of care for early breast cancer. Unlike mastectomy, in which the entire breast and lymph nodes are removed, lumpectomy involves only removal of the cancerous tissue and a margin of healthy tissue. Government initiatives to increase public awareness for early breast cancer detection are drastically increasing the number of patients eligible for BCS. Now, BCS is the most performed breast cancer surgery and accounts today for about 70% of all breast cancer surgeries. In counterpart, BCS brings about a risk for the patient to need to undergo an additional surgery in case that not all the cancerous tissue is removed. Re-operation rates (RoR) in BCS are evaluated at 30% on average. Re-operation in BCS is costly for hospitals (€20.000 per re-operation), inconvenient for patients and delays initiation of adjuvant therapies. There is a clinical need for improved intra-operative margin assessment (IMA) methods to assess breast cancer tumor specimen margins in real time in the operating room to decrease RoR. HistologTM Digital Solution allows surgeons real-time, accurate, affordable, whole margin breast tumor assessment through the highest resolution at cellular and subcellular level by using a user-friendly graphical interface supported by a differentiating Automating Reading CAD tool without the need of a pathologist. HistologTM Digital Solution is fully compatible with the gold standard post-operational H&E assessment since it does not destroy specimen and can be integrated with patient information systems. SamanTree Medical’s goal is to make of HistologTM Digital Solution the standard for IMA of breast cancer tumor margins, and decrease the RoR from the current 30% to less than 3%.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores